Sign In
Buy NDAQ
$81.61
-0.88 (-1.07%)
At Close: Jun 24, 2026
NeuroOne® Regains Compliance with Nasdaq Listing Requirements
10:56am, Tuesday, 04'th Feb 2025
EDEN PRAIRIE, Minn., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica
mF International Limited Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
08:30am, Tuesday, 04'th Feb 2025
HONG KONG , Feb. 4, 2025 /PRNewswire/ -- mF International Limited (the "Company" or "mF International") (Nasdaq: MFI), a Hong Kong-based experienced financial trading solutions provider, today announ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 04'th Feb 2025
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted e
Summarizes recent filings and next steps, previews upcoming proxy schedule Reaffirms and updates previously stated goal CHICAGO , Feb. 3, 2025 /PRNewswire/ -- Edward and Ludmila Smolyansky ("Founding
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:42pm, Monday, 03'rd Feb 2025
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small mole
S&P 500, Nasdaq 100 Close Lower | Closing Bell
04:38pm, Monday, 03'rd Feb 2025
Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Alix Steel, Scarlet Fu, Carol Massar and Tim Stenovec. ------
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 03'rd Feb 2025
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo
Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request
04:10pm, Monday, 03'rd Feb 2025
Ji'an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Co
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Feb 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company's Board of Directors granted
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Feb 2025
NEWTON, Mass. , Feb. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Feb 2025
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Feb 2025
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025,
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Monday, 03'rd Feb 2025
CLEVELAND, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:06pm, Friday, 31'st Jan 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
NioCorp Announces Closing of $5.0 Million Underwritten Offering Priced At-The-Market Under Nasdaq Rules
04:05pm, Friday, 31'st Jan 2025
CENTENNIAL, CO / ACCESS Newswire / January 31, 2025 / NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:NB) today announced the closing of its previously announced underwritten offering o
